FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.
Metrics to compare | 4881 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4881PeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −6.7x | −0.5x | |
PEG Ratio | 0.07 | −0.10 | 0.00 | |
Price/Book | 1.8x | 6.1x | 2.6x | |
Price / LTM Sales | 648.3x | 35.3x | 3.3x | |
Upside (Analyst Target) | - | 66.0% | 43.5% | |
Fair Value Upside | Unlock | 17.2% | 6.3% | Unlock |